Executive summary
US Patent 5,637,611 is a US-issued small-molecule composition-of-matter patent targeting substituted 1,2,3,4-tetrahydrocarbazole derivatives with specific “R1 substituent” amide-sidechain options (via n=0) and a defined “R2/R3” amino-substitution pattern. The claim set spans (i) broad compound coverage by a general formula (I), (ii) narrower species and salts, (iii) pharmaceutical compositions, and (iv) method-of-treatment claims tied to use as a “5-HT1-like agonist.” The enforceable scope in the US is concentrated in the defined formula boundaries and in the enumerated species claims (claims 4–7), with downstream coverage for formulations (claim 8–9) and therapeutic use (claims 10–11) depending on whether an accused product is within the structural definition and whether infringement theory relies on method-of-use rather than composition.
US Patent 5,637,611: What is the claim scope of the 1,2,3,4-tetrahydrocarbazole 5-HT1-like agonist formula?
How broad is claim 1 (general formula (I))?
Claim 1 covers “a compound of the general formula (I)” with structural constraints expressed through the substituent definitions you provided. The scope is driven by five gating features embedded in the claim:
- Core scaffold: 1,2,3,4-tetrahydrocarbazole framework is implied by the dependent enumerated species and typical interpretation of US claims tied to the underlying formula (I).
- R1 sidechain definition is narrow at n=0: You stated “R1 is a group --(CH2)n CONR5 R6 ; n is zero.” That makes the sidechain effectively “CONR5R6” attached directly through a methylene count of zero, eliminating a spacer.
- Amide N-substituents R5/R6 are limited to small alkyls/H: Each independently is hydrogen, methyl, ethyl, or propyl.
- R2 and R3 must not both be hydrogen: “R2 and R3 each independently represent hydrogen or C1-6 alkyl provided both are not hydrogen.” This allows at least one of R2 or R3 to be alkyl, while permitting one to be H and the other to be alkyl.
- Salts are included: “or a pharmaceutically acceptable salt thereof.”
Practical read-through for freedom-to-operate (FTO): An accused compound must land inside the tetrahydrocarbazole core with a directly attached amide (n=0) and have amide-N substituents restricted to H/methyl/ethyl/propyl combinations, plus a substitution pattern at the R2/R3 positions where not both are H.
Where does claim 1 stop?
Claim 1 stops at structural features that violate any of the following:
- Spacer length: n cannot be nonzero. Any analog with an additional methylene (n>0) falls outside claim 1.
- Amide N-substitution size: R5/R6 cannot include groups beyond H, methyl, ethyl, propyl. Larger alkyls or heteroalkyls are out.
- Both unsubstituted at R2/R3: If both R2 and R3 are hydrogen, claim 1 does not cover.
- Salt-only coverage: The claim is for compounds and their salts, so salt formation does not rescue a structurally out-of-bounds free base.
How does claim 2 narrow R2/R3?
Claim 2 limits “R2 and R3 each independently represent hydrogen, methyl or ethyl” (with the implicit framework from claim 1). It removes higher C1-6 alkyl variants and caps R2/R3 at methyl or ethyl or H, while retaining the “not both hydrogen” condition inherited from claim 1 logic.
How does claim 3 narrow amide N substituents?
Claim 3 limits “R5 and R6 each independently represent hydrogen or methyl.” This collapses the claim 1 amide-N space from {H, methyl, ethyl, propyl} to only {H, methyl}. Many potential analogs with N-ethyl or N-propyl amides would not infringe claim 3.
Which specific compounds are explicitly claimed in US 5,637,611? (Species claims 4–7)
Species claims provide “hard anchors” that can be easier to assert and easier to evaluate than general formula coverage. Your text lists the following:
Claim 4 (three specific species)
- 3-n-propylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
- 3-i-propylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
- pharmaceutically acceptable salt thereof
Scope implication: This locks in an isomer-specific propylamino substitution at the “3-” position (n-propyl and i-propyl) with a carboxamido at “6-” that aligns with the claim 1 amide architecture (n=0).
Claim 5 (four additional species)
- 3-(N-(methyl)ethylamino)-6-carboxamido-1,2,3,4-tetrahydrocarbazole
- 3-dimethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
- 3-ethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
- pharmaceutically acceptable salt thereof
Scope implication: This expands the amino substitution space to include:
- N-(methyl)ethylamino (mixed N-substitution on the amine, paired with the 6-carboxamido)
- dimethylamino
- ethylamino
These typically fall well within claim 1’s R5/R6 {H,methyl,ethyl,propyl} universe, but some may map more cleanly to claim 3’s {H,methyl} only if the species uses solely methyl/H on the relevant amide N.
Claim 6 (one species)
- 3-Benzylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
- or salt thereof
Claim 7 (one species)
- 3-Pyrrolidinyl-6-carboxamido-1,2,3,4-tetrahydrocarbazole
- or salt thereof
Key scope tension to note: Claim 6 and claim 7 appear to introduce benzylamino and pyrrolidinylamino groups at the “3-” position. In a typical mapping, those substitutions likely correspond to the “R2/R3” alkyl variables or to a different named substituent position on the scaffold. If “R2/R3 each independently represent hydrogen or C1-6 alkyl,” benzyl is not C1-6 alkyl (it is arylmethyl). Pyrrolidinyl is also not a simple C1-6 alkyl. That suggests the general formula mapping is not a 1:1 equivalence between “R2/R3” and the amino substituent described in the named species, or the supplied claim text has internal variable mapping that differs from a simplified reading of R2/R3 as only “C1-6 alkyl.” Either way, species claims 6–7 are explicit coverage for those embodiments, and they function as litigation and licensing focal points.
What protection does the patent provide for pharmaceutical compositions? (Claims 8–9)
Claim 8
“A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.”
Composition scope: broad across all claim 1 compounds and their salts.
Claim 9
“A pharmaceutical composition comprising a compound of claim 3 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.”
Narrower composition scope: only those compounds that meet claim 3’s stricter amide N substitution constraints (R5/R6 are hydrogen/methyl only).
Implication: If a product uses a compound that meets claim 1 but not claim 3, claim 8 is available; if it meets claim 3, both claim 8 and claim 9 are available.
What method-of-treatment claims are included and how do they limit infringement risk? (Claims 10–11)
Claim 10
“A method of treatment of a condition wherein a 5-HT1-like agonist is indicated… administering… an effective amount of a compound of claim 1.”
Scope nature: this is a method-of-use claim linked to the indication category “5-HT1-like agonist.” It does not require a specific disease name in the text you provided. It ties infringement to whether a patient is treated for a condition where 5-HT1-like agonism is indicated and the administered compound is within claim 1.
Claim 11 (narrowed substituent set)
“A method… wherein… R5 and R6 each independently represent hydrogen and methyl and R1 and R2 each represent hydrogen, methyl or ethyl provided R1 and R2 are not both hydrogen.”
Scope narrowing: claim 11 limits the administered molecule to embodiments matching those variable constraints. This is relevant when evaluating:
- whether the claimed method could be avoided by using analogs outside the restricted R1/R2 and amide N set, and
- whether regulatory labeling and clinical use fall under “5-HT1-like agonist” indication.
In litigation strategy terms: method-of-use claims are often asserted in combination with composition claims. If a generic does not practice a patented composition (structure outside claim 1), then method-of-use infringement depends entirely on product identity and potentially on labeling/indication evidence.
How many “layers” of patent scope does the claim set create? (Compound, salts, composition, method)
- Compound layer: claim 1 (broad formula), claim 2 (R2/R3 cap), claim 3 (R5/R6 cap).
- Species layer: claims 4–7 list specific substituents and salts.
- Composition layer: claims 8–9.
- Method layer: claims 10–11.
That layering matters for enforcement because defendants can sometimes design around by moving to:
- a neighboring spacer (n>0) to avoid claim 1,
- an amide N-ethyl or N-propyl to avoid claim 3,
- a substitution outside the claim’s enumerated/variable ranges to avoid both general formula and species.
However, design-around is harder when species claims are asserted because they force a closer match to named embodiments (claims 4–7).
What does the patent claim coverage imply for 5-HT1-like agonist drug classes and competitive molecules?
How would an R&D team map this onto candidate structures?
The fastest internal mapping is:
- Confirm the core scaffold is the tetrahydrocarbazole derivative matching the claim’s named species substitutions.
- Check the carboxamido placement (6-carboxamido in the species claims).
- Evaluate 3-position substitution identity: propylamino (n/i), N-(methyl)ethylamino, dimethylamino, ethylamino, benzylamino, pyrrolidinylamino.
- Verify whether the amide N-substitution equals H/methyl only (claim 3), or can include ethyl/propyl (claim 1 and species where relevant).
- Test the spacer constraint: n=0 in R1 is a key boundary.
What does “salt” do to infringement analysis?
Salt protection extends enforcement to the salt form used in the marketed product. If the free base is within scope, commercially used salts generally fall within claim reach unless a court construes “pharmaceutically acceptable” narrowly.
Is US 5,637,611 likely strong at the claim level, or vulnerable to design-around? (Scope quality analysis)
Strength indicators
- Clean variable caps: n=0 and restricted amide N substituents (in dependent claims) create definitive boundaries.
- Named species anchors: claims 4–7 provide explicit coverage for multiple embodiments, reducing reliance solely on general formula interpretation.
- Method claims: method coverage provides additional enforcement pathways even when only certain formulations are marketed, as long as the exact claimed structure is administered.
Design-around vectors suggested by the claim language
- Change n: if any competitor uses analogs with (CH2)n CONR5R6 where n>0, it avoids the “n is zero” limitation of claim 1.
- Change amide N substitution beyond R5/R6 set: using N-substituents not in {H,methyl,ethyl,propyl} avoids claim 1; outside {H,methyl} avoids claim 3.
- Avoid R2/R3 pattern: if both R2 and R3 are H, claim 1 is avoided (assuming mapping as written aligns with the scaffold).
- Avoid specific 3-amino substituents: choosing substitutions not captured by the listed species or not encompassed by the general formula variable definitions reduces species-claim exposure.
Patent landscape integration: What other patents typically co-exist around a US compound patent like 5,637,611?
Without a full bibliographic record (continuations, related families, prosecution history, and co-pending compounds/uses), the only accurate landscape statements are structural: US 5,637,611’s claim set indicates a standard IP stack that often includes:
- related process patents for synthesis of the same tetrahydrocarbazole compounds,
- intermediate patents covering protected intermediates used to make the amide and the 3-position amine,
- formulation patents beyond “composition with physiologically acceptable carrier,” including sustained-release or dosage-form-specific claims,
- follow-on salts patents for specific pharmaceutically acceptable salt forms,
- method-of-use patents for narrower indications even within “5-HT1-like” conditions.
Those are typical categories, but only the claims you provided can be treated as certain for US 5,637,611 itself. The structural claim architecture here is already sufficient to establish at least four potential infringement theories (compound, salt, composition, method) within the US.
Key takeaways
- US 5,637,611 is a tetrahydrocarbazole 5-HT1-like agonist patent with compound claims anchored by a general formula (I) plus dependent narrowing on substituents (notably n=0 and amide N substituents).
- The claim set includes explicit species coverage (claims 4–7) for multiple 3-position amino variants: n-propylamino, i-propylamino, N-(methyl)ethylamino, dimethylamino, ethylamino, benzylamino, and pyrrolidinylamino, each with salts.
- Composition claims (8–9) extend coverage to dosage formulations without requiring specific excipient types beyond “physiologically acceptable carrier.”
- Method-of-use claims (10–11) tie infringement to treatment of conditions where a 5-HT1-like agonist is indicated, with claim 11 further restricting to a subset of variable-defined compounds.
- The enforceable scope is strongest when an accused product matches both the n=0 carboxamido architecture and the amino substitution pattern captured by claim 1 and/or the listed species.
FAQs
What does “n is zero” mean for possible 1,2,3,4-tetrahydrocarbazole analogs?
It limits the R1 substituent to a direct CONR5R6 attachment with no intervening methylene units, so analogs with n>0 are outside the claim 1 structural definition.
Does the patent cover both free bases and pharmaceutically acceptable salts?
Yes. Each compound claim is written to include “a pharmaceutically acceptable salt thereof,” and the composition claims similarly include salts.
How do claims 2 and 3 narrow claim 1 in practical design-around terms?
Claim 2 caps R2/R3 to hydrogen, methyl, or ethyl. Claim 3 caps the amide N substituents R5/R6 to hydrogen or methyl.
Are the listed compounds protected only as compositions or also as methods?
Both. The patent includes compound claims and pharmaceutical composition claims (8–9), plus method-of-treatment claims tied to 5-HT1-like agonist use (10–11).
If a competitor uses a benzylamino or pyrrolidinylamino variant, is it covered?
Yes at the species level: claim 6 covers the benzylamino species and claim 7 covers the pyrrolidinyl species, each including salts.
References
- US Patent 5,637,611.
